GlassScriptPhysician profile
Audrey L Tanksley
NPI 1750524518
$9,557.13
in general payments reported to CMS, 2019-2025
24 companies · $7,575 in 2025
The $7,575 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $23.60 · 2021: $158 · 2022: $420 · 2023: $418 · 2024: $503 · 2025: $7,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,199 · Food and Beverage: $2,269 · Travel and Lodging: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,199.00 |
| Food and Beverage | $2,268.93 |
| Travel and Lodging | $2,028.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $7,279.10 | 2021-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $434.09 | 2019-2023 | Lynparza |
| Viiv Healthcare Company | $417.31 | 2024-2025 | Cabenuva, Apretude |
| Glaxosmithkline, LLC. | $246.52 | 2019-2023 | Bexsero, Pediarix |
| Gilead Sciences, INC. | $231.61 | 2019-2025 | Descovy |
| Merck Sharp & Dohme LLC | $179.98 | 2020-2025 | Capvaxive, M-M-R II, Vaxneuvance |
| Abbvie INC. | $179.31 | 2019-2024 | Vraylar |
| Orexo US, INC. | $97.94 | 2021-2023 | Zubsolv |
| Pear Therapeutics (US), INC. | $68.65 | 2022 | |
| Braeburn INC. | $66.74 | 2024 | Brixadi |
| Uswm, LLC | $54.63 | 2022 | |
| Pfizer INC. | $42.85 | 2019 | |
| Alkermes, INC. | $39.55 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.19 | 2022 | |
| Tris Pharma INC | $24.73 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $23.23 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $22.10 | 2025 | |
| Vanda Pharmaceuticals INC. | $19.99 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $19.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.75 | 2025 | Abilify Maintena |
| Cranial Technologies, INC | $16.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.37 | 2024 | Invega Sustenna |
| Coopersurgical, INC. | $14.33 | 2023 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $14.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Tanksley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.